Janux Therapeutics Inc (JANX) Stock Forecast & Price Target

Compare

496 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JANX Analyst Ratings

Strong Buy

14 Buy

1 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Janux

Therapeutics Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JANX Stock 12 Month Forecast

Average Price Target

$75.42

▲(117.41% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Janux Therapeutics Inc in the last 3 months. The average price target is $75.42 with a high forecast of $200.00 and a low forecast of $42.00. The average price target represents a 117.41% change from the last price of $34.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","66":"$66","111":"$111","156":"$156","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$75.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,66,111,156,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.71,41.886153846153846,55.06230769230769,68.23846153846154,81.41461538461539,94.59076923076924,107.76692307692306,120.94307692307692,134.11923076923077,147.29538461538462,160.47153846153847,173.6476923076923,186.82384615384615,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.71,32.30307692307692,35.89615384615385,39.48923076923077,43.082307692307694,46.675384615384615,50.26846153846154,53.861538461538466,57.45461538461539,61.04769230769231,64.64076923076922,68.23384615384616,71.82692307692308,{"y":75.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.71,29.732307692307693,30.754615384615384,31.776923076923076,32.79923076923077,33.82153846153846,34.84384615384615,35.86615384615385,36.88846153846154,37.91076923076923,38.933076923076925,39.95538461538462,40.97769230769231,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$75.42

Lowest Price Target$42.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

UBS

Not Ranked

UBS

$65→$57

Buy

64.31%

Upside

Reiterated

11/28/25

Janux Therapeutics Inc (JANX) Gets a Buy from UBS

Swayampakula Ramakanth

H.C. Wainwright

$70

Buy

101.79%

Upside

Reiterated

11/25/25

Promising Potential of Janux Therapeutics: Buy Rating on Strong Clinical and Growth Prospects

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Janux Therapeutics initiated with a Peer Perform at Wolfe ResearchJanux Therapeutics initiated with a Peer Perform at Wolfe Research

Soumit Roy

JonesTrading

$90→$65

Buy

87.37%

Upside

Reiterated

11/11/25

Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position

Karina Rabayeva

Truist Financial

$100

Buy

188.27%

Upside

Reiterated

11/10/25

Truist Financial Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)Reiterating our Buy rating with a $100 PT.

Etzer Darout

Barclays

$47→$48

Buy

38.37%

Upside

Reiterated

11/07/25

Barclays Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

Kelsey Goodwin

Piper Sandler

$42

Buy

21.07%

Upside

Reiterated

11/07/25

Piper Sandler Remains a Buy on Janux Therapeutics Inc (JANX)

Stephen Willey

Stifel Nicolaus

$45→$46

Buy

32.60%

Upside

Reiterated

11/07/25

Janux Therapeutics price target raised to $46 from $45 at StifelJanux Therapeutics price target raised to $46 from $45 at Stifel

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/07/25

Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential

Alec Stranahan

Bank of America Securities

$59→$58

Buy

67.20%

Upside

Reiterated

11/07/25

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

Oliver McCammon

LifeSci Capital

$100

Buy

188.27%

Upside

Reiterated

11/06/25

Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc.

Joshua Schimmer

Cantor Fitzgerald

$200

Buy

476.54%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

11/06/25

Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$47

Buy

35.49%

Upside

Initiated

09/17/25

Janux Therapeutics Inc (JANX) Receives a New Rating from Roth MKMJANX Initiated Overweight w/$47.00 PT at Barclays

Bradley Canino

Guggenheim

$72

Buy

107.55%

Upside

Initiated

09/03/25

Janux Therapeutics initiated with a Buy at GuggenheimJanux Therapeutics initiated with a Buy at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

UBS

Not Ranked

UBS

$65→$57

Buy

64.31%

Upside

Reiterated

11/28/25

Janux Therapeutics Inc (JANX) Gets a Buy from UBS

Swayampakula Ramakanth

H.C. Wainwright

$70

Buy

101.79%

Upside

Reiterated

11/25/25

Promising Potential of Janux Therapeutics: Buy Rating on Strong Clinical and Growth Prospects

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Janux Therapeutics initiated with a Peer Perform at Wolfe ResearchJanux Therapeutics initiated with a Peer Perform at Wolfe Research

Soumit Roy

JonesTrading

$90→$65

Buy

87.37%

Upside

Reiterated

11/11/25

Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position

Karina Rabayeva

Truist Financial

$100

Buy

188.27%

Upside

Reiterated

11/10/25

Truist Financial Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)Reiterating our Buy rating with a $100 PT.

Etzer Darout

Barclays

$47→$48

Buy

38.37%

Upside

Reiterated

11/07/25

Barclays Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

Kelsey Goodwin

Piper Sandler

$42

Buy

21.07%

Upside

Reiterated

11/07/25

Piper Sandler Remains a Buy on Janux Therapeutics Inc (JANX)

Stephen Willey

Stifel Nicolaus

$45→$46

Buy

32.60%

Upside

Reiterated

11/07/25

Janux Therapeutics price target raised to $46 from $45 at StifelJanux Therapeutics price target raised to $46 from $45 at Stifel

Matt Phipps

William Blair

―

Buy

―

Reiterated

11/07/25

Buy Rating for Janux Therapeutics: Promising Data and Strong Financial Position Highlight Growth Potential

Alec Stranahan

Bank of America Securities

$59→$58

Buy

67.20%

Upside

Reiterated

11/07/25

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

Oliver McCammon

LifeSci Capital

$100

Buy

188.27%

Upside

Reiterated

11/06/25

Promising Pipeline and Strategic Developments Justify Buy Rating for Janux Therapeutics Inc.

Joshua Schimmer

Cantor Fitzgerald

$200

Buy

476.54%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

11/06/25

Buy Rating on Janux Therapeutics Inc: Strong Financials and Promising Clinical Developments

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$47

Buy

35.49%

Upside

Initiated

09/17/25

Janux Therapeutics Inc (JANX) Receives a New Rating from Roth MKMJANX Initiated Overweight w/$47.00 PT at Barclays

Bradley Canino

Guggenheim

$72

Buy

107.55%

Upside

Initiated

09/03/25

Janux Therapeutics initiated with a Buy at GuggenheimJanux Therapeutics initiated with a Buy at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Janux Therapeutics Inc

1 Month

xxx

Success Rate

7/12 ratings generated profit

Average Return

+1.68%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +1.68% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

+2.36%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.36% per trade.

1 Year

Swayampakula RamakanthH.C. Wainwright

Success Rate

8/15 ratings generated profit

Average Return

+73.24%

reiterated a buy rating 5 days ago

Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +73.24% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+26.37%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +26.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JANX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JANX has received 23 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. JANX average Analyst price target in the past 3 months is 75.42.

Each month's total comprises the sum of three months' worth of ratings.

JANX Financial Forecast

JANX Earnings Forecast

Next quarter’s earnings estimate for JANX is -$0.65 with a range of -$0.94 to -$0.46. The previous quarter’s EPS was -$0.39. JANX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year JANX has Performed in-line its overall industry.

JANX Sales Forecast

Next quarter’s sales forecast for JANX is $143.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $10.00M. JANX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year JANX has Performed in-line its overall industry.

JANX Stock Forecast FAQ

What is JANX’s average 12-month price target, according to analysts?

Based on analyst ratings, Janux Therapeutics Inc’s 12-month average price target is 75.42.

What is JANX’s upside potential, based on the analysts’ average price target?

Janux Therapeutics Inc has 117.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JANX a Buy, Sell or Hold?

Janux Therapeutics Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.

What is Janux Therapeutics Inc’s price target?

The average price target for Janux Therapeutics Inc is 75.42. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $42.00. The average price target represents 117.41% Increase from the current price of $34.69.

What do analysts say about Janux Therapeutics Inc?

Janux Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of JANX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Janux Therapeutics Inc (JANX) Stock Forecast & Price Target

JANX Analyst Ratings

JANX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Janux Therapeutics Inc

JANX Analyst Recommendation Trends

JANX Financial Forecast

JANX Earnings Forecast

JANX Sales Forecast

JANX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts